Myron John Tong1, Surachate Siripongsakun1, Gaelen Stanford-Moore1, Leeyen Hsu1, Patrick Weijen Chang1, Lawrence Mitchell Blatt1. 1. Dr. Tong is affiliated with the Liver Center of Huntington Medical Research Institutes in Pasadena, California and with the Pfleger Liver Institute and the Division of Digestive Diseases at the David Geffen School of Medicine of the University of California in Los Angeles, California. Dr. Siripongsakun is affiliated with the Pfleger Liver Institute and the Division of Digestive Diseases at the David Geffen School of Medicine of the University of California in Los Angeles, California and with Chalubhorn Hospital in Bangkok, Thailand. Ms. Stanford-Moore, Mr. Hsu, and Mr. Chang are affiliated with the Liver Center of Huntington Medical Research Institutes in Pasadena, California. Dr. Blatt is affiliated with Alios Biopharma in South San Francisco, California.
Abstract
BACKGROUND AND AIMS: Hepatitis B virus (HBV) infection is a common cause of hepatocellular carcinoma (HCC) in the United States. This study evaluated the impact of surveillance and treatment on HBV-infected HCC patients and identified factors associated with survival. METHODS: From 1981 to 2010, 166 hepatitis B surface antigen (HBsAg)-positive HCC patients were evaluated. Fifty-eight patients had HCC detected by surveillance, while 108 patients presented with HCC. RESULTS: Compared to patients detected by surveillance, those presenting with HCC had more symptoms (65.7% vs 41.4%; P=.002), were more frequently outside of Milan criteria (73.7% vs 29.6%; P<.001), more often presented with diffuse tumors (23.2% vs 1.9%; P<.001), and had a shortened median survival time (9.5 months vs 18.7 months; P=.003). Patients who presented with diffuse tumors were younger and more often male (P=.002-.007), had a higher alpha-fetoprotein (AFP) level (P=.023), and had a median survival time of only 1.68 months. By multivariate analysis, factors that were significantly associated with mortality included diffuse tumors (hazard ratio [HR], 6.30; 95% confidence interval [CI], 3.14-12.66; P<.001), being outside of Milan criteria (HR, 2.02; 95% CI, 1.26-3.23; P=.005), albumin level (HR per 1 standard deviation decrease, 1.4; 95% CI, 1.15-1.72; P=.001), AFP level (HR per 1 log standard deviation increase, 1.38; 95% CI, 1.13-1.67; P=.001), and receiving liver transplantation versus other treatments (HR, 0.08-0.38; 95% CI, 0.03-0.87; P<.001 to P=.022). CONCLUSION: In the United States, HBV-related HCC is a common malignancy, especially among Asian immigrants. Identification of HBsAgpositive subjects and routine HCC surveillance are essential for improving survival in these patients.
BACKGROUND AND AIMS: Hepatitis B virus (HBV) infection is a common cause of hepatocellular carcinoma (HCC) in the United States. This study evaluated the impact of surveillance and treatment on HBV-infected HCCpatients and identified factors associated with survival. METHODS: From 1981 to 2010, 166 hepatitis B surface antigen (HBsAg)-positive HCC patients were evaluated. Fifty-eight patients had HCC detected by surveillance, while 108 patients presented with HCC. RESULTS: Compared to patients detected by surveillance, those presenting with HCC had more symptoms (65.7% vs 41.4%; P=.002), were more frequently outside of Milan criteria (73.7% vs 29.6%; P<.001), more often presented with diffuse tumors (23.2% vs 1.9%; P<.001), and had a shortened median survival time (9.5 months vs 18.7 months; P=.003). Patients who presented with diffuse tumors were younger and more often male (P=.002-.007), had a higher alpha-fetoprotein (AFP) level (P=.023), and had a median survival time of only 1.68 months. By multivariate analysis, factors that were significantly associated with mortality included diffuse tumors (hazard ratio [HR], 6.30; 95% confidence interval [CI], 3.14-12.66; P<.001), being outside of Milan criteria (HR, 2.02; 95% CI, 1.26-3.23; P=.005), albumin level (HR per 1 standard deviation decrease, 1.4; 95% CI, 1.15-1.72; P=.001), AFP level (HR per 1 log standard deviation increase, 1.38; 95% CI, 1.13-1.67; P=.001), and receiving liver transplantation versus other treatments (HR, 0.08-0.38; 95% CI, 0.03-0.87; P<.001 to P=.022). CONCLUSION: In the United States, HBV-related HCC is a common malignancy, especially among Asian immigrants. Identification of HBsAgpositive subjects and routine HCC surveillance are essential for improving survival in these patients.
Authors: Peter Ferenci; Michael Fried; Douglas Labrecque; J Bruix; M Sherman; M Omata; J Heathcote; T Piratsivuth; Mike Kew; Jesse A Otegbayo; S S Zheng; S Sarin; S Hamid; Salma Barakat Modawi; Wolfgang Fleig; Suliman Fedail; Alan Thomson; Aamir Khan; Peter Malfertheiner; George Lau; F J Carillo; Justus Krabshuis; Anton Le Mair Journal: J Gastrointestin Liver Dis Date: 2010-09 Impact factor: 2.008
Authors: F Y Yao; L Ferrell; N M Bass; J J Watson; P Bacchetti; A Venook; N L Ascher; J P Roberts Journal: Hepatology Date: 2001-06 Impact factor: 17.425
Authors: Adrian M Di Bisceglie; Andre C Lyra; Myron Schwartz; Rajender K Reddy; Paul Martin; Gregory Gores; Anna S F Lok; Khozema B Hussain; Robert Gish; David H Van Thiel; Zobair Younossi; Myron Tong; Tarek Hassanein; Luis Balart; Jacquelyn Fleckenstein; Stephen Flamm; Andres Blei; Alex S Befeler Journal: Am J Gastroenterol Date: 2003-09 Impact factor: 10.864
Authors: Debra T Choi; Hye-Chung Kum; Sulki Park; Robert L Ohsfeldt; Yu Shen; Neehar D Parikh; Amit G Singal Journal: Clin Gastroenterol Hepatol Date: 2018-10-26 Impact factor: 11.382
Authors: M J Tong; C Q Pan; S-H B Han; D S-K Lu; S Raman; K-Q Hu; J K Lim; H W Hann; A D Min Journal: Aliment Pharmacol Ther Date: 2018-02-26 Impact factor: 8.171